Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors ...Middle East

TAIPEI and SAN DIEGO, July 15, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that its new drug Pidnarulex (CX-5461) has been selected...

Hence then, the article about senhwa biosciences announces first patient dosed in nci sponsored pilot study of pidnarulex cx 5461 pharmacodynamics in patients with advanced solid tumors was published today ( Wednesday 16/07/2025 - 05:48 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors )

Also on site :

• ‘It’s all because of Putin’: RT drops Christmas song spoof (AI VIDEO)
• My Husband Revealed the Real Reason Why He Doesn’t Touch Me. I’m Horrified.
• LA Daily News All-Area girls flag football: Livier Andrade is the player of the year